Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Gross Margin (2017 - 2025)

Historic Gross Margin for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to 77.65%.

  • Puma Biotechnology's Gross Margin rose 137800.0% to 77.65% in Q3 2025 from the same period last year, while for Sep 2025 it was 76.91%, marking a year-over-year increase of 76200.0%. This contributed to the annual value of 72.06% for FY2024, which is 13400.0% down from last year.
  • As of Q3 2025, Puma Biotechnology's Gross Margin stood at 77.65%, which was up 137800.0% from 76.54% recorded in Q2 2025.
  • Puma Biotechnology's 5-year Gross Margin high stood at 80.79% for Q4 2022, and its period low was 63.87% during Q3 2024.
  • For the 5-year period, Puma Biotechnology's Gross Margin averaged around 75.48%, with its median value being 76.54% (2025).
  • Per our database at Business Quant, Puma Biotechnology's Gross Margin tumbled by -144900bps in 2023 and then soared by 137800bps in 2025.
  • Puma Biotechnology's Gross Margin (Quarter) stood at 78.51% in 2021, then grew by 3bps to 80.79% in 2022, then decreased by -18bps to 66.3% in 2023, then rose by 15bps to 76.44% in 2024, then grew by 2bps to 77.65% in 2025.
  • Its Gross Margin was 77.65% in Q3 2025, compared to 76.54% in Q2 2025 and 77.06% in Q1 2025.